Ultrasensitive C-peptide ELISA

(10-1141-01)

Kit format: 1 x 96 wells

Measurement range: 5 - 280 pmol/L (0.015 – 0.85 ng/mL)

Superior sensitivity of < 2.5 pmol/L (0.0076 µg/L)

No or minimal cross-reactivity to insulin or proinsulin

High specificity enables measurement of human C-peptide in mouse and rat models

CE/IVD labeled on select markets

Serum controls available: 10-1134-01 (US only) or 10-1164-01

TALK TO A PERSON

Description

The Ultrasensitive Mercodia C-peptide ELISA is a high-quality immunoassay for specific quantification of low levels of human C-peptide in serum, plasma, cell culture media, or urine.

The Ultrasensitive Mercodia C-peptide ELISA is a highly specific tool registered for in vitro diagnostics (IVD) use. It is calibrated against the International Reference Reagent for human C-peptide, IRR84/510. The specificity of the utilized antibodies enables measurement of human C-peptide without interference from insulin or proinsulin, and measurement of human C-peptide in mouse and rat models.

Each Mercodia C-peptide ELISA kit contains reagents for 96 wells, sufficient for 42 samples and one calibrator curve in duplicate. The microplate strip format (12 strips x 8 wells) is ideal when only a limited number of samples need to be analyzed.

Higher sensitivity can be achieved by using an alternative protocol described in technical note TN34-0144.

Mercodia Diabetes Antigen Control (10-1134-01 (US only) or 10-1164-01) is designed to be used as a two-level control in the Ultrasensitive C-peptide ELISA.

Test characteristics

Species

Human

Samples

Serum, EDTA and heparin plasma or urine

Sample volume

50 µL

Assay range

5 - 280 pmol/L (0.015 – 0.85 ng/mL)

Detection limit

≤2.5 pmol/L (0.0076 µg/L)

Incubation

1h + 1h + 30 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Insulin

< 0.0006 %

Proinsulin

5 %

Proinsulin (Des 31-32)

3 %

Proinsulin (Split 32-33)

2 %

Proinsulin (Des 64-65)

74 %

Proinsulin (Split 65-66)

10 %

directions for use Certificate of Analysis Safety Data Sheet

directions for use

LOT. NO.	DOCUMENT
35793	DfU - 10-1141-01 v. 17.0
35557	DfU - 10-1141-01 v. 17.0
35250	DfU - 10-1141-01 v. 17.0

Certificate of Analysis

LOT. NO.	DOCUMENT
35793	CoA - 10-1141-01
35557	CoA - 10-1141-01
35250	CoA - 10-1141-01

Safety Data Sheet

DOCUMENT
SDS - 10-1141-01

For other languages and previous versions: Technical Library

references

Wang, L., Lovejoy, N. F. & Faustman, D. L. (2012) Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay. Diabetes Care 35, 465–470. Read more >

Sackett, S. D. et al. (2018) Extracellular matrix scaffold and hydrogel derived from decellularized and delipidized human pancreas. Sci. Rep. 8, 10452. Read more >

Furuyama, K. et al. (2019) Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. Nature 567, 43–48. Read more >

Luk, A. O. Y. et al. (2019) Diabetes-related complications and mortality in patients with young-onset latent autoimmune diabetes: A 14-year analysis of the prospective Hong Kong Diabetes register. Diabetes Care 42, 1042–1050. Read more >